{"id":380927,"date":"2020-11-13T10:03:28","date_gmt":"2020-11-13T15:03:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380927"},"modified":"2020-11-13T10:03:28","modified_gmt":"2020-11-13T15:03:28","slug":"inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/","title":{"rendered":"Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry"},"content":{"rendered":"<div class=\"mw_release\">\n<p>IRVINE, Calif., Nov.  13, 2020  (GLOBE NEWSWIRE) &#8212; Inari Medical, Inc. (NASDAQ: NARI) (\u201cInari\u201d), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230 patients enrolled in its FLASH study. \u00a0FLASH is a real world registry to study the FlowTriever system in intermediate- and high-risk pulmonary embolism (\u201cPE\u201d) patients.\u00a0 The results were strongly positive.\u00a0 Just one death (0.4%) was reported at 30 days.\u00a0 By contrast, the national PERT Consortium<sup>\u00ae<\/sup> Quality Database recently showed 30-day mortality rates of 25.9% and 6.1% for high- and intermediate-risk PE patients.\u00a0 In addition, the FLASH Registry showed a readmission rate of 6.7%, compared to the nearly 25% readmission rate shown in the PERT Database.\u00a0 Efficacy data were equally compelling, showing normalization or near normalization in a battery of hemodynamic variables like pulmonary artery pressure, RV\/LV ratio, and heart rate, as well as dyspnea (shortness of breath) metrics.\u00a0 \u00a0<\/p>\n<p>FLASH is a 500-patient prospective, multicenter, single-arm registry evaluating real world patient outcomes after treatment of PE with FlowTriever. Interim data were obtained across 19 US sites, and results were presented virtually by National Principal Investigator, Catalin Toma, MD, Director of Interventional Cardiology at UPMC Heart &amp; Vascular Institute in Pittsburgh, PA at the American Heart Association (\u201cAHA\u201d) Scientific Sessions 2020.<\/p>\n<p>These data follow the presentation of equally compelling acute data from the same patient set delivered two weeks ago at the annual TCT meeting.\u00a0 The acute results showed, at 48 hours, no deaths, no cardiac injuries, no pulmonary injuries, no procedure-related clinical deteriorations, and no intracranial hemorrhages in this highly compromised PE patient population.\u00a0 The TCT data also showed clinically and statistically significant improvement in hemodynamic parameters while the patient was still on the table.\u00a0 Post-procedure median ICU stay was 0 days.\u00a0 The new FLASH data released at AHA extends the study follow-up period to 30 days and demonstrates the durability of these acute results with continued improvement in outcomes over time.<\/p>\n<p>\u201cFLASH has shown us that PE patients experience symptom relief and improved cardiac function immediately upon removal of significant clot burden.\u00a0 These outcomes continue to improve over time.\u00a0 In fact, for a high percentage of these patients, measurements for dyspnea, right heart strain, pulmonary artery pressure and heart rate actually normalized after FlowTriever thrombectomy.\u00a0 We believe this suggests that removal of large clot burden with the FlowTriever system not only has an important impact acutely, but might have an important positive effect on long term implications of PE, like CTED and CTEPH,\u201d said Dr. Toma.<\/p>\n<p>\u201cWith over 60% of patients in FLASH having no contraindication to lytics, the study data suggests that FlowTriever is emerging as a frontline therapy for intermediate and high-risk PE patients, regardless of patient eligibility for other treatment options.\u00a0 PE care pathways are evolving,\u201d said Thomas Tu, MD, Chief Medical Officer of Inari Medical. \u201cVenous thromboembolism (\u201cVTE\u201d) patients are central to everything that we do at Inari, and we remain committed to advancing the treatment of this disease through clinical research and the continued development of purpose-built devices.\u201d<\/p>\n<p>\n        <strong>About Inari Medical, Inc.<\/strong><br \/>\n        <br \/>Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Westwicke Partners<br \/>Caroline Corner<br \/>Phone +1-415-202-5678 <br \/>caroline.corner@westwicke.com<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDczOSMzODIzNDc2IzIxOTQ1MTM=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Inari Medical, Inc. (NASDAQ: NARI) (\u201cInari\u201d), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230 patients enrolled in its FLASH study. \u00a0FLASH is a real world registry to study the FlowTriever system in intermediate- and high-risk pulmonary embolism (\u201cPE\u201d) patients.\u00a0 The results were strongly positive.\u00a0 Just one death (0.4%) was reported at 30 days.\u00a0 By contrast, the national PERT Consortium\u00ae Quality Database recently showed 30-day mortality rates of 25.9% and 6.1% for high- and intermediate-risk PE patients.\u00a0 In addition, the FLASH Registry showed a readmission rate of 6.7%, compared to the nearly &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380927","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Inari Medical, Inc. (NASDAQ: NARI) (\u201cInari\u201d), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230 patients enrolled in its FLASH study. \u00a0FLASH is a real world registry to study the FlowTriever system in intermediate- and high-risk pulmonary embolism (\u201cPE\u201d) patients.\u00a0 The results were strongly positive.\u00a0 Just one death (0.4%) was reported at 30 days.\u00a0 By contrast, the national PERT Consortium\u00ae Quality Database recently showed 30-day mortality rates of 25.9% and 6.1% for high- and intermediate-risk PE patients.\u00a0 In addition, the FLASH Registry showed a readmission rate of 6.7%, compared to the nearly &hellip; Continue reading &quot;Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T15:03:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDczOSMzODIzNDc2IzIxOTQ1MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry\",\"datePublished\":\"2020-11-13T15:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/\"},\"wordCount\":650,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDczOSMzODIzNDc2IzIxOTQ1MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/\",\"name\":\"Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDczOSMzODIzNDc2IzIxOTQ1MTM=\",\"datePublished\":\"2020-11-13T15:03:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDczOSMzODIzNDc2IzIxOTQ1MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDczOSMzODIzNDc2IzIxOTQ1MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/","og_locale":"en_US","og_type":"article","og_title":"Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry - Market Newsdesk","og_description":"IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Inari Medical, Inc. (NASDAQ: NARI) (\u201cInari\u201d), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230 patients enrolled in its FLASH study. \u00a0FLASH is a real world registry to study the FlowTriever system in intermediate- and high-risk pulmonary embolism (\u201cPE\u201d) patients.\u00a0 The results were strongly positive.\u00a0 Just one death (0.4%) was reported at 30 days.\u00a0 By contrast, the national PERT Consortium\u00ae Quality Database recently showed 30-day mortality rates of 25.9% and 6.1% for high- and intermediate-risk PE patients.\u00a0 In addition, the FLASH Registry showed a readmission rate of 6.7%, compared to the nearly &hellip; Continue reading \"Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T15:03:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDczOSMzODIzNDc2IzIxOTQ1MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry","datePublished":"2020-11-13T15:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/"},"wordCount":650,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDczOSMzODIzNDc2IzIxOTQ1MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/","name":"Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDczOSMzODIzNDc2IzIxOTQ1MTM=","datePublished":"2020-11-13T15:03:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDczOSMzODIzNDc2IzIxOTQ1MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDczOSMzODIzNDc2IzIxOTQ1MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inari-medical-announces-presentation-of-positive-30-day-follow-up-results-from-first-patients-in-real-world-flash-registry\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380927"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380927\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}